Gliatech
This article was originally published in The Gray Sheet
Executive Summary
Receives investigational device exemption approval from FDA to commence clinical trials of its Adcon-A anti-adhesion barrier product designed to inhibit post-surgical scarring and adhesions following certain abdominal and colorectal surgeries. "Successful preclinical testing" of the resorbable, carbohydrate polymer liquid demonstrated that the product was "effective in reducing the severity and incidence of" post-operative abdominal adhesions, the Cleveland-based firm says